WILMINGTON, July 22, 2014 – AccuGenomics Inc., a molecular tools company focused on producing methods and quality controls required to standardize molecular testing has been issued a patent for a transcript abundance method used to predict risk of bronchial carcinoma in 20 pack year smokers. The patent has issued as US 8,765,368 & US 8,771,947 and is part of a patent portfolio exclusively licensed to AccuGenomics by the University of Toledo, Ohio.
“Over the years we have built a strong patent portfolio around the use of standardize molecular testing, with a focus on applications in cancer care”, said Dr. Tom Morrison, AccuGenomics CSO. “Recent scientific evidence suggests that individuals who improperly respond to lung injury induced by smoking are at higher risk of developing cancer. This improper response appears to be detectable by measuring dysregulation of RNA transcripts for proteins involved in tissue damage response. These patents cover the gene transcripts and algorithms that indicate lung cancer risk for a >20-pack year smoker. The algorithm was generated using AccuGenomics standardized qPCR method which simplify complex molecular tests while ensure highly reproducible and accurate results. Further, the method’s embedded quality controls provide needed quality assurances required to support complex molecular measurements. Our plan is to make this test, along with the standardized methodology, available for clinical laboratories wishing to offer lung cancer risk testing.”
About Bronchial Carcinoma
Lung cancer is the leading cause of cancer mortality in both men and women in the United States and in Europe, with cigarette smoking being the primary known risk factor. Early detection using methods such as low-dose spiral coaxial tomography hope to reduce lung cancer mortality through early detection. However, because as many as 90 million active or ex-smokers in the United States alone are candidates for routine screening, the combined low true positive rate and relatively high rate of false positives lead to high screening cost and unnecessary follow-up diagnostic testing.
About Standardized Testing
Deployable molecular tests based on transcript abundance signatures has proven unreliable due to its sensitivity to variations in reagent handling, reagent specificity, instrument drift, and specimen quality. The predictive performance of complex transcript abundance signatures is reduced by the method variation and drift. AccuGenomics offers several transcript abundance methodologies that control for these variations to ensure every measurement was made correctly. These methods are ideal for development of kits that make many abundance measurements from limited degraded samples.